Novo Nordisk (NVO) shares plummeted on July 31, 2026, following the announcement that its Phase 3 ZEUS cardiovascular outcomes trial failed to meet its primary endpoint. The drug in question, ziltivekimab, a human monoclonal antibody targeting the IL-6 ligand, showed no statistically significant reduction in major adverse cardiovascular events (MACE) compared to placebo. While ziltivekimab successfully achieved its biological target by reducing IL-6 and hsCRP levels, this did not translate into clinical MACE benefits in the high-risk patient population with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation.
The market's reaction was swift and severe. NVO's American Depositary Receipts (ADRs) plunged by 9.12% from their prior close of $51.61 to an intraday price of $46.91, equating to a loss of roughly $4.71 per share. This single-day decline erased approximately $19 billion from the company's market capitalization, with trading volume spiking to over 19 million shares, nearly double the recent daily average. The magnitude of the sell-off immediately raised questions given that ZEUS involves ziltivekimab, a pipeline asset, and not semaglutide, the active ingredient in Novo Nordisk's blockbuster GLP-1 drugs, Ozempic and Wegovy. Crucially, company management explicitly stated that the ZEUS outcome would not impact its previously communicated adjusted operating profit outlook for 2026, though a non-cash impairment charge would be recorded in the third quarter of 2026. This disconnect between a non-core trial failure, unchanged near-term guidance, and a substantial equity value erosion suggests the market may be over-extrapolating.
A closer look at Novo Nordisk's financials reveals a company still largely driven by its GLP-1 franchise, despite the headline setback. The strength of its core business contrasts sharply with its 2026 guidance, which anticipates a contraction primarily due to non-demand factors.
In the first quarter of 2026 (Q1 2026), Novo Nordisk reported adjusted sales of DKK 70,063 million, marking a 4% decline at constant exchange rates (CER) compared to Q1 2025. Adjusted operating profit also decreased by 6% CER to DKK 32,858 million. This contraction, however, needs context. Q1 2026 benefited from a significant one-off reversal of a US 340B Drug Pricing Program provision, which inflated reported (IFRS) sales by DKK 26.8 billion, masking the underlying pricing pressures and competitive dynamics that led to the adjusted sales decline.
Despite the negative headline growth, the obesity care segment continued its robust performance, with sales growing 22% at CER in Q1 2026 to DKK 20,912 million. This growth underscores the strong demand for Wegovy, which along with Ozempic and Rybelsus (all semaglutide-based), accounted for roughly 71% of total Q1 2026 reported sales. For the full year 2025, the company reported total net sales of DKK 309,064 million and an operating profit of DKK 127,658 million, representing CER growth of 10% and 6% respectively. The continued double-digit growth in obesity care and the sheer dominance of GLP-1 products in the revenue mix highlight that the current financial trajectory remains heavily tied to semaglutide, an asset unaffected by the ZEUS outcome.
Here is a summary of key financial performance metrics:
| Period | Revenue (DKK m) | Operating Profit (DKK m) | Diluted EPS (DKK) | Obesity Care Sales (DKK m) |
|---|---|---|---|---|
| Q1 2026 (Adj.) | 70,063 | 32,858 | 6.63 | 20,912 |
| FY 2025 | 309,064 | 127,658 | 23.03 | 82,347 |
| Q2 2025 | 76,857 | 33,449 | 5.96 | 19,528 (Wegovy) |
| Q1 2025 | 78,087 | 38,791 | 6.53 | 18,424 |
Note: Q1 2026 sales and operating profit are adjusted (non-IFRS) to exclude the 340B provision reversal for better comparability. Operating profit for FY 2025, Q2 2025, and Q1 2025 are IFRS figures.
The market's sharp reaction to the ZEUS trial's failure stems from a critical misreading of the drug involved. ZEUS tested ziltivekimab, an IL-6 ligand inhibitor, as a standalone cardiovascular treatment. This mechanism is entirely separate from glucagon-like peptide-1 (GLP-1) receptor agonism, which is the biological basis of Novo Nordisk's highly successful Ozempic and Wegovy.
As Chief Scientific Officer Martin Holst Lange stated in the ZEUS trial announcement, "ZEUS was designed to test whether inhibition of the IL-6 pathway could translate reductions in cardiovascular inflammation into fewer major cardiovascular events. Although ziltivekimab produced the expected biological effect, this did not result in MACE benefits in this population." Lange further emphasized that while ziltivekimab did not achieve the MACE benefit hoped for, it "does not change our strategic commitment to cardiovascular disease."
Crucially, Wegovy's own cardiovascular benefits are already well-established and FDA-approved. In March 2024, the FDA approved Wegovy to reduce the risk of major adverse cardiovascular events (MI, stroke, and cardiovascular death) in adults with cardiovascular disease and either obesity or overweight. This approval was based on the landmark SELECT trial, which demonstrated a 20% relative risk reduction in MACE for semaglutide. Furthermore, semaglutide has shown significant improvements in heart failure symptoms and functional capacity in patients with heart failure with preserved ejection fraction (HFpEF) in trials like STEP-HFpEF.
Therefore, the ZEUS failure has no direct read-across to the efficacy or regulatory status of Wegovy's cardiovascular label. The disappointment from ziltivekimab, which also reported a higher frequency of serious infections compared to placebo, pertains to a distinct scientific hypothesis and an asset with no current revenue contribution. The core GLP-1 cardiovascular story for Novo Nordisk remains fully intact and continues to be a major revenue driver, making the market's generalized "cardiovascular setback" interpretation largely misplaced.
The approximately $19 billion market capitalization loss on ZEUS day demands a rigorous look at what investors were truly pricing in. Analyst models had previously attributed a relatively modest value to ziltivekimab. For example, UBS estimated ziltivekimab's contribution to Novo Nordisk's net present value (NPV) at only 1.7%, translating to roughly $3.5 billion to $4 billion of enterprise value on a pre-ZEUS company valuation of around $230-250 billion. Even optimistic scenarios from Morgan Stanley, which projected ziltivekimab peak annual sales of up to $5 billion if effective across multiple indications, would struggle to justify a $19 billion haircut. This implies the market's reaction exceeded the direct financial impact by more than fivefold, suggesting a repricing of broader sentiment and pipeline optionality.
Novo Nordisk's valuation multiples already reflected a "reset year" for 2026. Prior to ZEUS, the stock was trading at a trailing price-to-earnings (P/E) ratio of approximately 15.0x (inferred from the current ~13.6x post-drop), and an enterprise value-to-EBITDA (EV/EBITDA) of around 11x. Following the ZEUS announcement, the trailing P/E compressed further to about 12.8x, representing a significant 46% discount to its 10-year average P/E of 23.77x. Similarly, its EV/EBITDA dropped to a range of 8.45x-10.7x, a substantial 50% below its 5-year average of 23.3x. This places Novo Nordisk's valuation multiples closer to those of diversified large-cap pharmaceutical companies, rather than a high-growth GLP-1 leader like Eli Lilly (LLY), which trades at a P/E in the 30-40x range and an EV/EBITDA around 20x.
The sharp decline therefore seems to stem from investors applying an incrementally higher discount to Novo Nordisk's broader "beyond GLP-1" diversification story and attaching greater weight to pipeline risk. This occurred despite management's explicit statement that 2026 adjusted operating profit guidance remains unchanged, further emphasizing the overreaction to an asset that had minimal embedded value to begin with.
Even after the ZEUS setback, several tangible risks persist for Novo Nordisk, which contribute to the market's cautious sentiment, regardless of ziltivekimab's direct financial impact.
First, GLP-1 competitive pressure from Eli Lilly's tirzepatide (Mounjaro/Zepbound) remains a primary structural challenge. Tirzepatide has demonstrated superior weight loss efficacy, sometimes exceeding 20% in trials, compared to semaglutide's high-teens. While Novo Nordisk's 2026 guidance for -4% to -12% sales and operating profit growth at constant exchange rates implicitly accounts for competitive intensity and pricing, a significant share shift to Lilly could imply multi-billion DKK annual revenue erosion for Novo by 2029.
Second, US pricing and policy headwinds continue to weigh on profitability. The DKK 26.8 billion (~$4.2 billion) provision reversal linked to the US 340B Drug Pricing Program significantly boosted reported sales in Q1 2026, but this one-off benefit will not recur. Moreover, the US Inflation Reduction Act's Medicare drug price negotiation, expected to impact high-spend drugs like semaglutide, could lead to material price cuts of 25-60%, further compressing margins on crucial US GLP-1 sales.
Third, the semaglutide patent cliff presents a long-term threat, particularly outside the US. While the core US compound patent for semaglutide (Ozempic, Wegovy, Rybelsus) extends to December 2031 (with some protection until 2032-2033), generic semaglutide was approved in Canada in May 2026 due to an administrative lapse. Similar expiries are expected in other international markets from 2026-2028. Given that the semaglutide franchise generated well over DKK 200 billion in 2025, a 20-25% erosion of revenue in exposed markets by 2028 could put DKK tens of billions at risk, significantly impacting overall profit given the high margins of GLP-1 products.
Finally, the R&D efficiency and pipeline risk are amplified by the ZEUS failure. Novo Nordisk's R&D expenditure represented 16.8% of sales in 2025 (over DKK 52 billion). While pharma R&D is inherently risky, the high-profile failure of ziltivekimab, following earlier disappointments outside the GLP-1 space, raises questions about internal hurdle rates and the reliability of non-GLP-1 diversification bets. This could lead investors to apply a lower R&D productivity multiple, further depressing the company's valuation.
Wall Street's outlook on Novo Nordisk is currently characterized by a cautious "Buy" consensus, but with significant underlying dispersion and a recent shift towards more conservative ratings, even before the ZEUS trial readout.
The aggregate analyst data shows a "Buy" consensus from 39 analysts, with 22 Buy ratings, 13 Holds, and 3 Sells. However, the uniformity of price targets in some data feeds (e.g., median, high, and low all at $45.00) suggests a data normalization quirk rather than a true lack of dispersion. More comprehensive views, such as from the Wall Street Journal, revealed a wider 12-month price target range from a low of $30.35 to a high of $69.34, with an average target of $49.77 (pre-ZEUS).
Post-ZEUS, NVO's current price of $46.91 sits just below the WSJ's median target of $47.04 and above the more conservative $45.00 consensus from some feeds. Notably, several prominent firms downgraded Novo Nordisk earlier in 2026, signaling a pre-existing cautious sentiment. Goldman Sachs downgraded its rating from Buy to Neutral with a price target of $41.00 in March 2026, while JP Morgan shifted from Overweight to Neutral in February 2026. Deutsche Bank also moved from Buy to Hold in March 2026, citing limited upside from the ZEUS trial and broader patent cliff concerns.
The analyst commentary following the ZEUS announcement largely echoed this sentiment, framing the result as a strategic negative but one with limited near-term financial impact. Jefferies, for instance, noted that the decline seemed disproportionate given ziltivekimab's small portfolio contribution. This blend of "strategic negative" and "financially limited" reinforces the idea that much of the Street had already de-rated Novo Nordisk due to GLP-1 competitive pressures and patent risks, making the post-ZEUS sell-off an intensification of existing concerns rather than a fresh fundamental hit.
Here is a selection of recent analyst views and targets:
| Firm | Rating (Current) | Price Target | Date (if change) |
|---|---|---|---|
| Goldman Sachs | Neutral | $41.00 | 2026-03-02 (Downgrade) |
| JP Morgan | Neutral | N/A | 2026-02-24 (Downgrade) |
| Deutsche Bank | Hold | $43.00 (DKK 290) | 2026-06-19 |
| Jefferies | Hold | $42.00 | 2026-07-31 (Commentary) |
| Barclays | Equal Weight | $43.00 | 2026-07-31 (Commentary) |
| API Consensus | Buy | $45.00 (Median) | 2026-07-31 |
| WSJ Average | Buy | $49.77 | Late Jul 2026 (Pre-ZEUS) |
The strongest argument against the "overreaction" thesis is that the market is not overreacting, but rather correctly repricing the heightened long-term earnings concentration risk in GLP-1 and the overall R&D pipeline uncertainty. Losing a multi-billion dollar opportunity like ziltivekimab (which had a consensus peak sales estimate of approximately $3 billion) at a time of impending GLP-1 patent expiry in some regions and intensified competition means the market is right to discount future growth options. The market, in this view, is pricing future lost revenue optionality, not just current earnings. The roughly $19 billion market capitalization loss, therefore, represents a mark-to-market adjustment for a future growth pathway that has now closed.
This objection holds weight, especially when considering the sheer dominance of the GLP-1 franchise, which accounted for approximately 94% of Novo Nordisk's total sales in fiscal year 2025. With generic semaglutide already approved in Canada (May 2026) and US/EU patents set to expire between 2028 and 2032-2033, the vulnerability to competitive erosion is real. The ZEUS failure, signaling that not all diversification bets will succeed, naturally intensifies concerns about Novo Nordisk's ability to offset future GLP-1 headwinds. The company's own 2026 guidance of a 4% to 12% decline in adjusted sales and operating profit at constant exchange rates already reflects these underlying pressures.
However, this argument overstates the specific impact of ziltivekimab while underestimating Novo Nordisk's broader strategic response. As established, analyst models valued ziltivekimab's contribution to Novo Nordisk's NPV at only about $3.5 billion to $4 billion. The market's $19 billion haircut is therefore five times larger than the explicit value of the lost asset, indicating an over-generalized sentiment hit rather than a precise financial adjustment. Furthermore, Novo Nordisk is not relying solely on ziltivekimab for diversification. Its robust next-generation obesity pipeline, including CagriSema (a cagrilintide-semaglutide combination) and zenagamtide (amycretin, a GLP-1/amylin dual agonist), is progressing rapidly through Phase 3 trials. These assets aim to extend both patent protection and competitive efficacy beyond current semaglutide, providing a significant hedge against future GLP-1 commoditization.
The company's substantial capital expenditure commitments of approximately DKK 55 billion in 2026, coupled with an expected total cash return to shareholders exceeding DKK 60 billion, signal management's continued confidence in the long-term cash generation of its core GLP-1 business. This confidence is not reflected in the stock's post-ZEUS valuation multiples, which are trading at a 46% discount to its 10-year average P/E.
The true test of whether the ZEUS sell-off was an overreaction will lie in the 2027-2028 GLP-1 volume growth and pricing stability. If Novo Nordisk can successfully maintain its greater than 50% obesity GLP-1 market share and its next-generation assets demonstrate compelling competitive profiles, the current discount will prove unwarranted.
Novo Nordisk's 9.1% share price drop following the ZEUS trial failure appears to be an overreaction, driven by a market that conflated a non-core pipeline asset's setback with the company's robust and intact GLP-1 core. The roughly $19 billion market capitalization loss far outstrips ziltivekimab's modest embedded value of approximately $3.5 billion to $4 billion, suggesting a significant sentiment-driven over-penalty. While the ZEUS outcome is a strategic disappointment, it has no direct bearing on the already FDA-approved cardiovascular benefits of Wegovy, nor does it impact the company's reiterated 2026 adjusted operating profit outlook. Novo Nordisk's GLP-1 franchise continues to exhibit strong demand and impressive volume growth, with next-generation assets poised to extend its competitive edge.
Given this context, we believe the stock is currently trading at a compelling discount relative to its long-term potential. An entry zone between $45.00 and $46.00, close to the current post-ZEUS price and the lower end of analyst consensus, presents an attractive opportunity. Our 12-month price target is set at $55.00, implying a return to a more normalized valuation multiple closer to the higher end of the current analyst range, which would reflect a more appropriate premium for its industry-leading GLP-1 franchise and pipeline. This target is supported by sustained GLP-1 momentum and successful progression of its next-generation obesity programs. This bullish stance would be invalidated by a sustained break below the 52-week low of $35.12, particularly if accompanied by an unexpected and material deterioration in GLP-1 market share, pricing power, or a failure in its pivotal CagriSema or zenagamtide trials. Novo Nordisk's enduring GLP-1 strength means its current depressed multiple offers a compelling risk-reward.
Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.
